TABLE OF CONTENTS
Title page……………………………………………………………………………….ii
Declaration………………………………………………………………………………iii
Approval page ………………………………………………………………………….iv
Dedication page ………………………………………………………………………….v
Acknowledgement………………………………………………………………………vi
Table of content ………….……………………………………………………………viii
List of tables .……………………….………………………………………………….xii
Abstract …………………………………………..…………………………………….xv
CHAPTER ONE: Introduction …………………………………………..……………1
1.0: Historical background ………………………..……………………………………..1
1.1: Statement of the problem ………………………………………………………….12
1.2: Objective of the study…………………………………………………….……….14
1.2.1: General objective ..………………………………….…………………………..14
1.2.2: Specific objective………………………………………………………………..14
CHAPTER TWO: Literature review…………………………….……………………15
2.0: Awareness of respondents to ADR reporting scheme/guideline…………………..15
2.1: Attitude of professionals in different settings of healthcare to ADR reporting……17
ix
2.2: ADR reporting practices in different countries……………………………………18
2.3: ADR reporting practices in different categories of health professionals …………20
2.4: Commonly reported ADR…………………………………………………………23
2.5: factors influencing ADR reporting by healthcare professionals……………………26
2.5.1: Potential obstacles to ADR reporting……………………………………………26
2.5.2: Factors encouraging the reporting of ADR………………………………………29
2.6: Training of healthcare professionals on ADR reporting…………………………..32
2.7: Methods of improving ADR reporting…………………….………………………34
CHAPTER THREE: Methodology………………………………….…………….…37
3.0: background of the study area………………………….…………………………..37
3.1: Target population…………………………………………………………….……39
3.2: Design of the study……………………………………………………………….40
3.3: Criteria for selection of health facilities and respondents………………………..40
3.4: Sample size …………………………………………………………………….…41
3.5: Method of data collection…………………………………………………………42
3.6: Pretesting …………………………………………………………………………43
3.7: Data entry and analysis…………………………………………………………….43
x
3.8: Ethical consideration…………………………….…………………………………43
3.9: Informed consent…………………………………..……………………………….43
3.10: Challenges to carrying out the research……………………………….…………44
CHAPTER FOUR:
Results……………………………….…………………………………………………46
4.0: Demography of respondents………………………………………………………46
4.1: Awareness of respondents to ADR reporting scheme/guideline…………………50
4.2: Knowledge of respondents to ADR reporting criteria……………………………54
4.3: Attitude of respondents to ADR reporting……………………………………….57
4.4: Practice of ADR reporting among health professionals studied…………………72
4.5: Factors influencing ADR reporting by respondents………………………………75
4.6: Training of respondents on ADR reporting………………………………….……86
4.7: Respondents’ suggestions to improve ADR reporting…………………….……..91
CHAPTER FIVE:
Discussions………………………………………………………………..…………..93
CHAPTER SIX: Conclusion and Recommendations……………….………………101
6.0: Conclusion…………………………………………………….…………………101
6.1: Recommendations………………………………………..………………………102
xi
References…………………………………….……………..………………………..104
xii
LIST OF TABLES
Table 1: Suggested methods of improving ADRs reporting in Nigeria ……………….35
Table 2: Socio demographic variables of respondents .………………………………..46
Table 3: Distribution of respondents by health facility ………………………………..49
Table 4: Distribution of health professional’s awareness to ADR reporting scheme…..50
Table 5: Distribution of awareness of respondents to ADR reporting scheme by
Health facility …………………………………………………………………………..53
Table 6: Distribution of respondent’s Knowledge of ADR reporting criteria by
Profession ..…………………………………………………………………………….54
Table 7: Distribution of respondent’s knowledge of ADR reporting criteria by health
facility ………………………………………………………………………………….56
Table 8: Attitude of health professionals to ADR reporting ………………………..…57
Table 9: Distribution of health professionals who believe ADR reporting to be
their professional responsibility ………………………………….…………………….59
Table 10: Distribution of respondents who believe that ADR reporting is their
professional responsibility by Health facility ……………………..………………….62
Table 11: Distribution of health professionals who suspected ADR but did
not report …………………………………………………………..…………………..63
xiii
Table 12: Health facility distribution of respondents who suspected but did not
report ADR………………….………………………………………………………….66
Table 13: Professional distribution of respondents who did not report because of
uncertainty that reaction was caused by drug ………………………………………….67
Table 14: Professional distribution of respondents who did not report because
the reaction was too trivial to be reported …………………………………………….68
Table 15: Professional distribution of respondents who did not report because
the reaction was too well known to be reported……………………………………….69
Table 16: Professional Distribution of respondents who would report if the
medication was prescribed for their patient by another physician…………………….70
Table 17: Professional distribution of respondents who would report if the
patient had bought the medication without prescription ……………………………….71
Table 18: Distribution of respondent who reported ADR by category ………………..72
Table 19: Distribution respondent who reported ADR by Health facilities………..…74
Table 20: Factors influencing ADR reporting by health care professionals…….……..75
Table 21: Distribution of respondents who stated unavailability of electronic
reporting as obstacle to reporting ……………………………………………………..77
Table 22: Distribution of respondents who stated unavailability of reporting
xiv
forms as obstacle to reporting …………………………………………………………80
Table 23: Health facility distribution of respondents who stated unavailability
of reporting forms as obstacle to reporting……………………………………………..82
Table 24: Distribution of respondents who stated ignorance as obstacle
to reporting …………………………………………………………………………….83
Table 25: Health facility distribution of respondents who stated ignorance
as obstacle to reporting ………………………………………………………….……..85
Table 26: Distribution of respondents with training on ADR reporting ……………….86
Table 27: Health facility distribution of respondents with training on ADR reporting..89
Table 28: Distribution of the type of training respondents had on ADR reporting …..90
Table 29: Suggested ways to improve ADR reporting in Nigeria …………………….91
xv
ABSTRACT
This descriptive cross sectional survey was conducted on healthcare professionals
working at different healthcare facilities in Nnewi North L.G.A of Anambra state to
determine their awareness, attitude and practice to ADR reporting. The research was
carried out after an approval from Nnamdi Azikiwe University teaching Hospital ethical
committee. Written consent was obtained from the heads of different health facilities
and informed consent was obtained from individual respondents during the
administration of the questionnaires. Simple random sampling technique was used to
select the health facilities studied and numbers of different professional groups sampled
was proportionately determined. Consecutive recruitment method was used until the
required sample was attained.
A total of 372 respondents [including 241 (64.8%) nurses/related health care workers,
109 (29.3%) doctors and 22 (5.9%) pharmacists] were studied. Two hundred and twenty
one (59.4%) respondents were not aware of the existence of ADR reporting scheme in
Nigeria. 241 (64.8%) of them lack the knowledge of reporting guideline. Though 85.8%
of the respondents believe ADR reporting to be their professional responsibility, 310
(83.3%) suspected an ADR without reporting it, Uncertainty of reactions caused by
drug, ignorance on how to report, fear, unavailability of reporting forms/guideline and
lack of electronic means of reporting were mentioned as obstacles to ADR reporting.
There was indeed poor awareness (40.6%), poor attitude, and poor practice (0.9%) of
ADR reporting among health professionals working in Nnewi North Local Government
Area of Anambra state.
1
CHAPTER ONE
INTRODUCTION
1.1. HISTORICAL BACKGROUND
Adverse drug reaction (ADR) has been defined in so many ways. WHO defines ADR
as any response to a drug which is noxious and unintended, and which occurs at doses
normally used in man for prophylaxis, diagnosis, therapy of disease, or for the
modification of physiological function1. A definition by Karch and Lasagna2 puts ADR
as any response to a drug that is noxious and unintended, and that occurs at doses used
in humans for prophylaxis, diagnosis, or therapy, excluding failure to accomplish the
intended purpose. The American society of health system Pharmacists (ASHP) 3
defines a significant ADR as any unexpected, unintended, undesired, or excessive
response to a drug that;
Requires discontinuing the drug (therapeutic or diagnostic),
Requires changing the drug therapy,
Requires modifying the dose (except for minor dosage adjustments),
Necessitates admission to a hospital,
Prolongs stay in a health care facility,
Necessitates supportive treatment,
Significantly complicates diagnosis,
Negatively affects prognosis, or
Results in temporary or permanent harm, disability, or death.
2
Consistent with this definition, an allergic reaction (an immunologic hypersensitivity,
occurring as the result of unusual sensitivity to a drug) and an idiosyncratic reaction (an
abnormal susceptibility to a drug that is peculiar to the individual) are also considered
ADRs. Other definitions of ADRs exist, including that of the United state Agency for
Food and Drug Administration (FDA) 4.
For reporting purposes, FDA categorizes a serious ADR as one in which the patient’s
outcome is death, life-threatening (real risk of dying), hospitalization (initial or
prolonged), disability (significant, persistent, or permanent), congenital anomaly, or
required intervention to prevent permanent impairment or damage. It should be noted
that side effect {an effect with predictable frequency; an effect whose occurrence are
related to the size of the dose; or an expected, well-known reaction resulting in little or
no change in patient management (e.g., drowsiness or dry mouth due to administration
of certain antihistamines or nausea associated with the use of antineoplastics)}, drug
withdrawal, drug-abuse syndromes, accidental poisoning, and drug-overdose
complications should not be defined as ADRs.4
TYPES OF ADVERSE DRUG RACTION
ADRs may be categorized in five groups. The two most common are dose related
effects (type A: augmented) and effects related to abnormal interaction between patient
and drug (type B: bizarre). 5
Type A: Adverse drug reactions:
Type A: (augmented) reactions are normal pharmacologic effects of the drug
exaggerated to the point of being undesirable or intolerable for patients. Type A ADRs
are the most common, accounting for 75-80% of those reported. 4 Reactions of this type
3
are also called ‘predictable’, because they are predictable from the pharmacology of the
drug, whether caused by an excessive effect of the main pharmacological action (such
as hypotension with antihypertensive drugs), or by an undesired secondary
pharmacological action (such as the dose-dependent adrenal suppression caused by
inhaled corticosteroids, which is of particular concern in children) 4.
Type A reactions are dose-related, occurring at a dose that is too high for the individual,
and tend to have a relatively high morbidity. However, because type A reactions are
usually slow in onset, the associated mortality rate is lower than in type B reactions. A
type A drug reaction is more likely to occur with drugs that have a narrow therapeutic
index (such as theophylline), and tend to occur more often in elderly people and
neonates.
In general, drugs causing type B and serious type A reactions need to be stopped,
whereas drugs causing less severe type A reactions may be continued at a reduced
dose.4 For type A reactions, other management options might include substitution of a
similar but more selective drug, or giving additional drugs to antagonize the unwanted
effects of the primary agent 3, 6. Examples – Warfarin or heparin, which causes bruising;
or diphenhydramine, which causes drowsiness. Another form of type A reaction
involves a drug’s recognized pharmacologic property other than the primary desired
one. For example, b-adrenergic blocking agents exert their effect on receptors other than
those targeted in the heart and vasculature, leading to the potential of bronchospasm due
to b-blockade of certain receptors in the pulmonary tree. E.g.
4
Periorbital swelling caused by a proton pump inhibitor.
Type B Adverse drug reactions:
Type B (bizarre) reactions are often more severe adverse effects unrelated to the known
pharmacologic action of the drug and include most immunologic reactions. Unless
patients are tested for antibody markers, these reactions are unpredictable and may or
may not be dose-dependent. Type B reactions account for about 20-25% of those
reported3. Because these reactions are not predictable from the pharmacology of the
drug {such as Amoxicillin Clavulanic acid causing cholestatic jaundice, anaphylactic
reaction to penicillin (rash)}. They are also known as unpredictable idiosyncratic
reactions. Individual susceptibility to this type of reaction varies greatly.
Type B reactions are usually rapid in onset and there is a higher risk of mortality than in
type A reactions7. Patients need to be able to recognize the warning signs of such a
reaction if it is known to have occurred before with their medication.
Type B reactions are often allergic, sometimes involving anaphylaxis, which typically
occurs on second or third exposure to the drug7. Patients with a history of anaphylaxis
5
and atopic individuals with a history of asthma are more likely to experience
anaphylaxis. Other type B reactions include those attributable to unpredictable genetic
factors that can affect drug metabolism2. Type B reactions usually require the causative
drug to be stopped, because the reaction can occur at any dose, and the reaction is
usually serious.
Erythematous rash caused by an unknown drug.
Other types of ADRs include Type C, D and E.5 While Type C ADR is associated with
long-term use and dose accumulation (e.g., phenacetin and interstitial nephritis or
antimalarials and ocular toxicity, NSAID induced renal failure), Type D is a delayed
effects (dose independent) and occurs some time after use of drug {such as
Carcinogenicity (e.g immunosuppressants) and Teratogenicity (e.g., fetal hydantoin
syndrome and limb defects with thalidomide in first trimester and)}.7 On the other hand,
type E is a withdrawal syndrome associated with end of use of the drug. It is related to
discontinuation that is too abrupt, for example, addisonian crisis after steroid
withdrawal 7, 8. ADR can also be classified based on
Onset of event: { Acute (within 60 minutes), Sub-acute (1 to 24 hours), Latent
( > 2 days )} and
6
Severity of reaction: {Mild ( bothersome but requires no change in therapy),
Moderate (requires change in therapy, additional treatment, hospitalization),
Severe (disabling or life-threatening)}
RISK GROUPS FOR ADVERSE DRUG REACTION
All drugs have the potential to cause ADRs, although most produce no ill effects in
most patients. ADRs are more likely to occur if doses above the usual recommended
level are given, but there are several other predisposing factors/groups2,9,10 including
Older patients due to altered drug handling; for example: reduced drug metabolism and
elimination by the liver and kidneys, poor drug distribution, and increased sensitivity to
the effects of medications; the young (neonates, particularly premature babies) due to
poor development of metabolizing and elimination enzymes, increased sensitivity and
underdevelopment of physiological systems, such as renal function and the blood-brain
barrier and the fact that many medicines have not been developed in pediatric doses and
are used off-label, so that dosage in children is often inaccurate9. Women because they
are more susceptible to the toxic effects of drugs, including commonly used agents such
as digoxin, heparin and captopril. Also, few data are available on the safety of
medicines used in pregnant and lactating women. Women may be inadvertently exposed
to unsafe products and there is a particular lack of information, education and guidance
in resource-limited settings9; Patients with impaired hepatic or renal function;
Patients taking several drugs: Polypharmacy increases the risk of ADRs and the
likelihood of ADRs increases sharply with the number of drugs administered mainly
due to drug interactions. Mistakes may also occur if drug regimens are complicated and
7
involve several drugs. The number of drugs prescribed should always be kept to a
minimum to reduce the risk of drug interactions, and very clear instructions on how to
take them should be given, particularly to older patients; Atopic individuals: Patients
with a history of anaphylaxis and atopic individuals with a history of asthma are more
likely to experience anaphylactic reactions (type B adverse effects); Individuals with
specific genetic variations in drug-metabolising enzymes: Genetic variability in
drug-metabolising enzymes is an important contributing factor to the incidence of
ADRs (particularly type B reactions), in some individuals 10. Certain ethnic groups have
been identified as being more susceptible to ADRs with particular drugs because of
genetic polymorphism. For example, glucose-6-dehydrogenase (G6PD) deficiency,
which predisposes to some drug-induced haemolytic anaemias, is more common in
people who are African, in Kurdish and Iraqi Jews, and in some Mediterranean people
and Filipinos; Individuals with co-existing disease: Certain disease states can
precipitate ADRs to certain drugs if the disorder alters the pharmacokinetics of a drug
(absorption, distribution, metabolism, elimination), or if it increases the individual’s
sensitivity to the action of a drug (for example, patients with obstructive airway disease
are more sensitive to the bronchoconstriction caused by beta-blockers); Variations in
drug formulations that result in the delivery of higher than expected quantities of
the active drug can cause ADRs; and Error at any stage in the supply of a medication;
for example, confusion can arise over milligrams and micrograms and between similar
drug names or a drug might be administered at the wrong dose, or to the wrong site.
8
FREQUENCY AND OCCURRENCE OF ADRs
ADRs are common. A study by general practitioners estimated that the presenting
symptom of 1.7% of their consultations over a six month period was a manifestation of
an ADR 11. Furthermore, 2-6% of hospital admissions are for ADRs. 12,13 Although a
shorter timeframe is more common, ADRs can occur months or years after a drug was
started and may not be obvious unless a thorough drug history is taken. These long-term
ADRs can be predictable: type A reactions (such as osteoporosis with corticosteroids, or
bladder cancer in patients taking cyclophosphamide), or idiosyncratic, type B reactions
(such as, pulmonary fibrosis with amiodarone). The frequency of adverse reactions are
generally described in the manufacturer’s product literature as follows14.
common → occurring in 1:100 to 1:10 of the patients.
very common → more than 1:10
uncommon → 1:1,000 to 1:100
rare → 1:10,000 to 1 :1,000
Very rare → less than 1:10,000.
AVOIDING ADRs
Though ADR is common, a study on ADRs in nursing homes suggest that more than
half of the events are preventable 15-18 and that 70% are associated with monitoring
errors15. Also, serious ADRs are more likely to be preventable than those of a less
serious nature15. Understanding the causes of ADRs is essential to efforts to decrease
their frequency and severity.
9
WHO’S ROLE TO REPORT ADRs
While pharmacists head the establishment of ADRs programs in health institutions and
facilitate activities surrounding reporting of ADRs, the core reporting of ADRs is a
collective activity of all health professionals.11,20,21 According to The Guide for
Detecting and reporting of Adverse Drug reactions19, all healthcare
professionals/workers including doctors, dentists, pharmacists, nurses, traditional
medicine practitioners and other health professionals are requested to report all
suspected adverse reactions to drugs including orthodox medicines, X-ray contrast
media, medical devices, cosmetics, traditional and herbal medicines. This guide also
stressed that it is vital to report even when it is uncertain that the medicine in question is
the actual cause of the reaction.
MANAGEMENT OF A SUSPECTED ADR
The symptoms of an ADR can be similar to those of diseases with other causes, and
there are few specific clinical or laboratory methods to differentiate them7. When trying
to determine whether an unwanted effect is an ADR, it may be helpful to find out
whether the reaction has been reported before for the drug in question.
ADRs must be treated according to their cause and severity. In general, drugs causing
type B and serious type A reactions need to be stopped, whereas drugs causing less
severe type A reactions may be continued at a reduced dose. Specific management
according to Oliver Jones7 is as follows:
10
For type A reactions, the management is simply reduction in the dose or withdrawal of
the medication. Other management options might include substitution of a similar but
more selective drug, or giving additional drugs to antagonize the unwanted effects of
the primary agent.
By contrast, type E reactions require reintroduction of the drug and more gradual
withdrawal. Type C or D reaction may be irreversible or only partially reversible on
drug withdrawal.
Type B reactions are both uncommon, unpredictable, and have high morbidity and
mortality. The first step is always the immediate withdrawal of the drug. If the reaction
is mild, no further intervention may be necessary. Urticarial rashes, and to a lesser
extent non-urticarial rashes, may be treated with antihistamines such as
chlorpheniramine and an adrenocortical steroid. In more severe cases, these drugs may
be given intravenously or intramuscularly. If angioedema develops with threatened
laryngeal oedema, consideration should be given to adrenaline.
Anaphylaxis is a medical emergency. High skilled help should be summoned, including
an anaesthetist. The patient should be positioned flat, with feet raised and airway
secured. Oxygen should be administered and 0.5-1.0mg of adrenaline given
intramuscularly as first line treatment (equivalent to 0.5-1.0ml of 1:1000 adrenaline).
This is repeated every ten minutes according to cardiovascular parameters and clinical
improvement. Chlorpheniramine (10-20mg) should also be administered by slow
intravenous injection, and hydrocortisone (100-300mg), though the onset of action of
the latter may not be for several hours. Further deterioration may necessitate
11
intravenous fluids, nebulised inhalers, and intubation or tracheostomy. Other ADRs
may involve any body system and manifest in several different ways. The correct
management of these patients should be considered on an individual basis. Often this is
delayed by failure to consider an ADR as the underlying cause of a patient’s
deterioration.
Other management options include the use of “tracer” drugs that are used to treat
common ADRs (e.g., orders for immediate doses of antihistamines, epinephrine, and
corticosteroids), or stat orders for laboratory assessment of therapeutic drug levels and
Provision of supportive or palliative care e.g., hydration, glucocorticoids, warm / cold
compresses, analgesics or antipruritics, rechallenge or desensitization.7, 15
Reports of birth defects related to thalidomide use in pregnant women prompted FDA
to develop an adverse event surveillance program in 196122 and with the amended Food,
Drug, and Cosmetic Act of 1962, drug manufacturers were required to report any
adverse events associated with their products.
The World Health Organization (WHO), in 1968, created the International Drug
Monitoring Program for the purpose of collecting information about Adverse Drug
Reactions (ADR) that were not observed during clinical drug trials.23 This program has
been exceptional in identifying the early signs of ADRs .24 ADR monitoring and
reporting programs encourage ADR surveillance, facilitate ADR documentation,
promote the reporting of ADRs, provide a mechanism for monitoring the safety of drug
use in high-risk patient populations, and stimulate the education of health professionals
regarding potential ADRs25.
12
1.1. STATEMENT OF THE PROBLEM:
Globally, physicians are faced everyday with problems of adverse drug reactions
(ADRs) 12, 26 , 27 and about 95% of such cases go unreported Worldwide 28,29. Even
though they are under-reported worldwide, they are much more under-reported in
Nigeria30. Studies have also shown that adverse drug reaction (ADR) is the 4th to 6th
cause of death in the United States26, 27. Studies conducted in developed countries have
consistently shown that approximately 5% of hospitalized patients are admitted into
hospital as a result of an adverse drug reaction while 6-10% of inpatients experience a
serious ADR during hospitalization12. The percentage of hospital admissions due to
ADRs in some countries is approximately 10% 31-34 and treatment of ADRs imposes a
high (15-20 %) financial burden on health care 35, 36. According to Med Watch 2, the
Food and Drug Administration’s (FDA’s) Office of Drug Risk Assessment has stated
that these numbers are vastly underestimated, as its research has shown that only 1% of
ADRs are reported. The purpose of ADR reporting is to reduce the risk associate with
prescribing and administration and ultimately improve patients care, safety and
treatment outcome.
The National Agency for Food, Drug Administration and Control (NAFDAC)
therefore introduced pharmacovigilance in 2004 to encourage ADR monitoring and
reporting in Nigeria. Unfortunately, there is very limited information about adverse
drug reactions in developing countries32, including Nigeria due to poor reporting of
ADRs. The information which we receive on adverse drug effect from other countries
may not be applicable to Nigeria due to various differences that may influence
patient’s response 19 including;
13
Disease and prescribing practices;
Treatment seeking behavior e.g. self medication;
Genetics, Diet, Traditions of people e.g. high carbohydrate, fat, kola nut
consumption rate etc;
Drug manufacturing process used which influence pharmaceutical, quality and
composition;
Drug distribution and use including indications, dose, storage and availability;
The use of traditional and complementary drugs ( e.g. herbal remedies) which
may pose specific toxicological problems when used alone or in combination
with other drugs; and
Racial differences.
This study was designed to determine the awareness, attitude and practice of ADR
reporting among health care professionals working in Nnewi North L. G. A., Anambra
state with a view to encourage health professionals to see ADR monitoring and
reporting as a professional obligation. With improvement on ADR reporting in this area,
ADR induced morbidity, mortality and death will be drastically reduced.
14
1.2. OBJECTIVE OF THE STUDY
1.2.1. GENERAL OBJECTIVE
To determine the awareness, attitude and practice of ADR reporting among
health care professionals working in Nnewi North L. G. A, Anambra state.
1.2.2. SPECIFIC OBJECTIVES
To find out the level of awareness of health professionals in Nnewi North L.G.A
to the national Adverse drug reaction reporting scheme/guideline.
To access the attitudes of health professionals in different settings of health care
in Nnewi North L.G.A [Health posts, Primary Health centres (PHC), Private
hospitals and tertiary health institution] towards the reporting of ADR.
To compare the ADR reporting practices of different categories of health care
professionals.
To determine factors influencing the reporting of ADR by health professionals.
To determine the proportion of health practitioners that has ever had training on
ADR reporting.
DISCLAIMER: All project works, files and documents posted on this website, UniProjectTopics.com are the property/copyright of their respective owners. They are for research reference/guidance purposes only and some of the works may be crowd-sourced. Please don’t submit someone’s work as your own to avoid plagiarism and its consequences. Use it as a reference/citation/guidance purpose only and not copy the work word for word (verbatim). The paper should be used as a guide or framework for your own paper. The contents of this paper should be able to help you in generating new ideas and thoughts for your own study. UniProjectTopics.com is a repository of research works where works are uploaded for research guidance. Our aim of providing this work is to help you eradicate the stress of going from one school library to another in search of research materials. This is a legal service because all tertiary institutions permit their students to read previous works, projects, books, articles, journals or papers while developing their own works. This is where the need for literature review comes in. “What a good artist understands is that nothing comes from nowhere. All creative work builds on what came before. Nothing is completely original.” - Austin Kleon. The paid subscription on UniProjectTopics.com is a means by which the website is maintained to support Open Education. If you see your work posted here by any means, and you want it to be removed/credited, please contact us with the web address link to the work. We will reply to and honour every request. Please notice it may take up to 24 – 48 hours to process your request.
